Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 15, 2017




(Exact name of registrant as specified in its charter)




Delaware   001-38096   26-3648180

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


79 T.W. Alexander Drive

4501 Research Commons, Suite 100

Research Triangle Park, NC

(Address of principal executive offices)   (zip code)

Registrant’s telephone number, including area code: (919) 213-9835



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 7.01 Regulation FD Disclosure.

The attached slides were presented by G1 Therapeutics, Inc. at the Wedbush PacGrow Healthcare Conference on August 15, 2017.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


99.1    Presentation for Wedbush PacGrow Healthcare Conference.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



/s/ Gregory J. Mossinghoff

      Gregory J. Mossinghoff
      Chief Business Officer

Date: August 17, 2017







99.1    Presentation for Wedbush PacGrow Healthcare Conference.

Slide 1

Presentation for Wedbush PacGrow Healthcare Conference August 15, 2017 Mark Velleca MD, PhD Chief Executive Officer Exhibit 99.1

Slide 2

Forward-looking statements This presentation and the accompanying oral commentary contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, known as the PSLRA, that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, development plans, regulatory activities, competitive position, potential growth opportunities, use of proceeds and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission.

Slide 3

G1 Therapeutics: clinical-stage oncology company Advancing the validated CDK4/6 inhibitor space Three wholly owned drug candidates addressing distinct multi-billion dollar markets Trilaciclib is first-in-class with compelling clinical data; currently in four Phase 2 trials G1T38 has best-in-class potential versus Ibrance and Kisqali G1T48 (oral SERD) potentially first/best-in-class; on track for 4Q17 IND Multiple clinical read-outs and value inflection points in 2018

Slide 4

Proven industry leaders with more than 75 years of oncology experience Mark Velleca, MD, PhD – Chief Executive Officer Greg Mossinghoff – Chief Business Officer Jay Strum, PhD – Chief Scientific Officer Board of Directors Seth Rudnick, MD – board chairman Glenn P. Muir – audit committee chair Christy Shaffer, PhD – Hatteras Venture Partners Fred Eshelman, PharmD – Eshelman Ventures Tyrell Rivers, PhD – MedImmune Ventures Mark Velleca, MD, PhD – CEO Experienced leadership, well financed Management team ~ $96m in private financing Cormorant Franklin Templeton Rock Springs Capital RA Capital ~ $107m IPO - May 22, 2017 Nasdaq: GTHX Investors Raj Malik, MD – Chief Medical Officer Andrew Witty – former CEO, GSK Terry Murdock – SVP, Development Operations

Slide 5

Nobel Prize-winning science FDA accelerated approval of Pfizer’s Ibrance for breast cancer in 2015 $2.1 billion revenue in 2016 $7 billion in estimated global peak sales Significant therapeutic and market potential in multiple other cancers G1 is the only biopharma with two clinical-stage CDK4/6 inhibitors: trilaciclib G1T38 From: Nat Rev Drug Disc 2015;14:130-146 CDK4/6 is a validated and promising target

Slide 6

CDK4/6 typically required for cell cycle progression To grow and proliferate, all cells progress through four phases of the cell cycle G1 and G2 are gap or growth phases S phase: DNA synthesis M phase: cell division

Slide 7

Selective CDK4/6 inhibition arrests cells in G1 Selective CDK4/6 inhibition blocks Rb phosphorylation and progression from G1 to S phase: a cytostatic effect

Slide 8

G1T38: arrests tumor cells in G1 G1T38 blocks proliferation; potentiates tumor cell death when combined with other targeted therapy (e.g. SERD) G1T38 Highly selective CDK4/6 inhibitor with best-in-class potential Differentiated from Ibrance, Kisqali and abemaciclib Potential “backbone therapy” for multiple combination regimens in many CDK4/6-dependent tumors Tumor cell

Slide 9

CDK4/6-independent tumor cell Many cancers do not require CDK4/6 to grow CDK4/6-independent tumors can proliferate even in the presence of a CDK4/6 inhibitor Common CDK4/6-independent tumors include SCLC and TNBC Chemotherapy is typically used to treat these cancers Chemotherapy kills other cells such as hematopoietic stem and progenitor cells (HSPCs)

Slide 10

HSPC HSPCs are the “reservoir” from which all blood and immune system cells are formed HSPCs are damaged by chemotherapy, causing myelosuppression and immunosuppression, limiting anti-tumor efficacy CDK4/6-independent tumor cell Hematopoietic stem and progenitor cells (HSPCs) require CDK4/6

Slide 11

HSPC CDK4/6-independent tumor cell Trilaciclib: transiently arrests HSPCs in G1 Short-acting IV therapy for patients with CDK4/6-independent tumors Preserves HSPCs from damage by chemo: myelopreservation Potential to improve tolerability/efficacy of chemotherapy, and chemo/ checkpoint inhibitor combos First-in-class approach Trilaciclib Trilaciclib transiently blocks progression through the cell cycle (G1 arrest), protecting HSPCs from damage by chemotherapy

Slide 12

G1’s CDK4/6 inhibitors: broad potential Drug Tumor type MOA Dosing Combination Initial indications Trilaciclib CDK4/6- independent Preserves HSPCs, enhances immune system function IV, intermittent Chemotherapy and/or checkpoint inhibitor SCLC, TNBC G1T38 CDK4/6- dependent Stops tumor cell proliferation Oral, daily Growth-signaling inhibitors (e.g., SERD, EGFRi) ER+, HER2- breast cancer, NSCLC Two distinct compounds rationally designed and optimized by G1, leveraging 10 years of expertise in CDK4/6 biology and chemistry Each drug has potential to be backbone therapy for multiple combination regimens

Slide 13

Key advantages of trilaciclib and G1T38 G1T38: overcoming competitors’ liabilities, potentially best-in-class Trilaciclib: a first-in-class approach Rationally designed as a short-acting IV therapy given prior to chemo No known competitor (including PFE, NVS, LLY) PFE, NVS and LLY inhibitors do not have the PK profile required for this setting Competition G1T38 Shorter half-life: potential for continuous daily dosing and less neutropenia Clean hERG/QT, no DILI High selectivity versus CDK2 and other kinases Ibrance - PFE Long half-life leads to drug accumulation, neutropenia, and dosing holiday Kisqali - NVS Neutropenia/dosing holiday, QT prolongation, DILI (additional monitoring) abemaciclib - LLY High incidence of diarrhea due to insufficient selectivity (CDK2)

Slide 14

G1’s development pipeline G1 owns IP and worldwide commercial rights to all compounds 13 issued composition-of-matter and methods-of-use patents

Slide 15

Key anticipated milestones through 2Q18 Trilaciclib (iv CDK4/6i) G1T38 (oral CDK4/6i) 1st line- SCLC Phase 2a 2nd/3rd-line SCLC Phase 2a metastatic TNBC Phase 2 1st line- SCLC, Ph2 (+ Tecentriq) EGFRm NSCLC Phase 1b/2 (+ Tagrisso) ER+, HER2- BC Phase 1/2a 3Q17 4Q17 1Q18 2Q18 G1T48 (oral SERD) Phase 1 initiated top-line randomized data Phase 1b initiated IND filed ER+, HER2- BC Ph1b/2a (+ Faslodex) Phase 1b enrollment completed; Phase 2a initiated enrollment completed IND filed Phase 1b preliminary data enrollment completed enrollment continuing (through 2018) enrollment completed (2Q17)

Slide 16

trilaciclib development program

Slide 17

Opportunity to improve chemotherapy treatment outcomes and synergize with checkpoint combinations Trilaciclib preserves HSPCs and enhances immune system function during chemotherapy

Slide 18

Trilaciclib addresses shortcomings of SOC lineage-specific support after damage by chemotherapy accelerates bone marrow exhaustion exacerbates myeloid skewing and chronic lymphopenia Trilaciclib: preserves all blood lineages Current SOC: growth factors and transfusions IV administration before chemo, prevents HSPC damage mitigates bone marrow exhaustion attenuates myeloid skewing, preserves lymphocytes

Slide 19

Rationally designed product profile Reduce suppression of all hematopoietic lineages by protecting HSPCs from damage by chemotherapy (myelopreservation) Reduce clinically relevant consequences of myelosuppression - e.g. febrile neutropenia (FN) - and reduce overall cost of care from hospitalizations, growth factor support, transfusions Use with multiple chemotherapies in patients with CDK4/6-independent tumors: SCLC, TNBC, bladder, head and neck, others Dosing regimen fits with standard clinical practice IV infusion of trilaciclib prior to chemotherapy Potential to increase anti-tumor activity and impact ORR/PFS/OS by: enabling maintenance of planned chemotherapy dose and schedule enhancing immune system function in context of chemo-mediated tumor cell death

Slide 20

Trilaciclib value proposition - base case: myelopreservation-only, CDK4/6-independent ~ 1 million patients/year receive chemotherapy (US only) ~ 300,000 patients with CDK4/6-independent tumors eligible for trilaciclib predominantly CDK4/6-independent: SCLC, TNBC, HPV+ H&N, bladder, cervical, sarcomas CDK4/6-independent subsets of: NSCLC, HER2+ BC, uterus, esophagus, CRPC, CRC Worldwide market potential exceeds several billion dollars annually assumes conservative patient capture rate and pricing Several upside case scenarios with compelling data in hand efficacy enhancement synergy with checkpoint inhibitor/chemo combos use in CDK4/6-dependent tumors Potential to be “backbone therapy” for multiple chemo regimens and checkpoint/chemo combinations

Slide 21

Three ongoing POC trials in extensive–stage SCLC Setting Combination Phase Total # Patients Primary Endpoints Secondary Endpoints Current Status 1st-line carboplatin (AUC=5) and etoposide (100 mg/m2) 1b: open label 2a: randomized (1:1), placebo-controlled 96 1b: 19 2a: 77 myelo-preservation: e.g. FN, transfusions ORR, PFS, OS 2a enrollment completed; top-line data expected in 1Q18 2nd/3rd-line topotecan (0.75 mg/m2 and 1.5 mg/m2) 1b: open label 2a: randomized (2:1), placebo-controlled ~ 120 1b: 32 2a: ~ 90 myelo-preservation: e.g. FN, transfusions ORR, PFS, OS 2a enrollment completion anticipated 2Q18 1st-line carboplatin/ etoposide/ Tecentriq 2: randomized (1:1), placebo-controlled ~ 100 OS ORR, PFS, myelo-preservation enrolling Compelling open-label data: no febrile neutropenia (FN) in 51 patients, >250 cycles chemo (historical FN rates ~ 30% with topotecan)

Slide 22

1st-line SCLC Phase 1b/2a trial Trilaciclib + etoposide/carboplatin (EP) in patients with newly diagnosed extensive-stage SCLC (PS 0-2) Combination schedule in 21-day cycles 30 min IV infusion of trilaciclib prior to EP on days 1-3 Completed open-label Phase 1b trial 19 patients enrolled, 17 evaluable for efficacy data presented at ASCO 2017 (Rocha Lima et al) Randomized, double-blind, placebo-controlled Phase 2a trial ongoing enrollment completed in 2Q17 (77 patients, 1:1 randomization) top-line data expected in 1Q18

Slide 23

Robust myelopreservation: mean CBCs above clinically relevant cytopenia thresholds for all blood lineages; no febrile neutropenia cohort 2 (n=9): Phase 2a dose of trilaciclib (240 mg/m2) S = baseline, EC = end cycle 1st-line SCLC complete blood counts (CBCs): no clinically relevant myelotoxicity Data from Rocha Lima et al, ASCO 2017

Slide 24

1st-line SCLC: encouraging anti-tumor activity Data from Rocha Lima et al, ASCO 2017

Slide 25

1st-line SCLC: encouraging anti-tumor activity Data from Rocha Lima et al, ASCO 2017

Slide 26

SCLC 1b/2a trials: conclusions and plans Phase 1b data provides strong evidence of myelopreservation in both first-line and second/third line settings No febrile neutropenia: 51 open-label patients, >250 chemo cycles Better than historical overall response rates in first-line Both studies in randomized, placebo-controlled Phase 2a Top-line data from first-line study expected in 1Q18 Potential to move rapidly into pivotal trials

Slide 27

SCLC: trilaciclib/chemo/immune checkpoint inhibitor combination trial Trilaciclib: robust immune preservation when given with chemotherapy – preserves lymphocyte numbers/function Compelling preclinical data for combining trilaciclib/chemo with checkpoint inhibitor Non-exclusive collaboration with Genentech to evaluate trilaciclib/chemo/Tecentriq across multiple indications 2Q17: initiated a randomized placebo-controlled Phase 2 trial in 1st-line ES-SCLC (chemo/Tecentriq +/- trilaciclib) Setting Combination Phase Total # Patients Primary Endpoints Secondary Endpoints Current Status 1st-line carboplatin/ etoposide/ Tecentriq 2: randomized (1:1), placebo-controlled ~ 100 OS ORR, PFS, myelo-preservation enrolling

Slide 28

Trilaciclib enhances chemo/checkpoint efficacy in syngeneic CDK4/6-independent tumor model MC38 tumor growth (median) Trilaciclib: highly significant impact on: ORR complete responses survival Repeat experiments demonstrate: reproducibility trilaciclib has no activity as monotherapy (expected with CDK4/6-independent tumor) similar effects with anti-PD-1 and other chemo regimens (data in 2017 AACR poster) IP dosing regimen (for both experiments shown): anti-PD-L1 100ug/animal D1,4,8,11; oxaliplatin 10mg/kg D1,8,15 trilaciclib 100mg/kg 30’ before oxaliplatin

Slide 29

Expansion to other indications: TNBC Significant unmet medical need in triple-negative breast cancer (TNBC) Gemcitabine/carboplatin + trilaciclib in first/second-line metastatic TNBC ~ 90 patient, randomized, open-label Phase 2 trial initiated 1Q17 primary endpoints: myelopreservation (e.g. FN, transfusions) secondary endpoints: ORR, PFS, OS Immunophenotyping to evaluate trilaciclib effects on T-cells Expect ~ 20% patients to have CDK4/6-dependent tumors pathological confirmation of tumor CDK4/6 status, but enrolling “all comers” will correlate response-rate with CDK4/6 status to determine applicability of approach in broader population (i.e. CDK4/6-dependent tumors)

Slide 30

G1T38 development program

Slide 31

Company CDK4/6 Hormone Signaling Kinase Growth Factors Pathway Inhibitors B-Cell Signaling Novartis ü ü ü ü Pfizer ü ü ü ü Lilly ü ü ü Roche ü ü ü ü AstraZeneca ü ü ü ü Bayer ü ü ü Takeda ü ü ü Amgen ü ü Gilead ü ü Sanofi ü ü ü Abbvie ü Astellas ü ü ü J&J ü ü Bristol Myers ü Celgene ü ü Merck ü G1 ü ü Only CDK4/6 inhibitor not owned by big pharma CDK4/6 inhibitors most effective when used in combination with other targeted therapies G1 owns both components of marketplace-validated combo (SERD + CDK4/6i) Less neutropenia, potential for daily dosing without holiday No QT, DILI issues Better GI tolerability Best-in-class potential Strategic opportunities for G1T38: building combination oncology regimens Significant scarcity value

Slide 32

2017 publications Molecular Cancer Research (Stice et al, preclinical data in prostate cancer) Oncotarget (Bisi et al, preclinical data in breast cancer and NSCLC) Extensive preclinical validation and differentiation head-to-head studies with Ibrance (Bisi et al, 2017) Drug well-tolerated in 75 subject Phase 1a HNV trial no DLTs or grade 3/4 AEs differentiated PK profile (shorter t1/2, larger Vd than Ibrance and Kisqali) Encouraging early results in Phase 1b/2a breast cancer trial (in combination with Faslodex) pharmacodynamic activity observed at first dose level well-tolerated GI profile; no liver or CV AEs G1T38 differentiation: robust preclinical package and encouraging initial clinical data

Slide 33

G1T38: backbone therapy for multiple combination regimens - potential development paths Cancer Indication/Line G1T38 with: Rationale Breast HR+/HER2- 1L G1T48 Approval of palbociclib with fulvestrant; extension of mPFS from 4.6 to 9.5 months (PALOMA-3, Turner et al 2015, Cristofanilli et al 2016). G1T38 + G1T48 enhances efficacy and extends time to resistance in preclinical models (Wardell et al AACR 2017). HR-/HER2+ TDM1 failures > 3L trastuzumab + lapatinib CDK4/6 inhibitors re-sensitize HER2+ cancers to HER2 blockade (Goel et al 2016, Malumbres 2016, Witkiewicz et al 2014). G1T38 + lapatinib/trastuzumab enhances efficacy and extends time to resistance in preclinical models. NSCLC EGFRm: 1L EGFRi CDK4/6 + EGFR inhibition overcomes resistance in preclinical models (Zhou et al 2016). G1T38 + EGFRi enhances efficacy and extends time to resistance in NSCLC EGFRT790M murine model (Bisi et al 2017). EGFRm: EGFRi failures, 2L osimertinib ALKi failures, 2L alectinib ALK and CDK4/6 inhibition demonstrates synergy in preclinical models (Wood et al 2016). KRASm, > 2L MEKi MEKi + CDK4/6i has significant anti-KRAS–mutant NSCLC activity (Tao et al 2016, LeBlanc et al 2016). Prostate CRPC 1L/2L AR-blocker Prostate tumor cells are highly dependent on cyclin D for cellular proliferation (Balk et al 2008). G1T38 demonstrates robust preclinical efficacy in CRPC models (Stice et al 2017). Lymphoma MCL, MZL, CLL, FL, DLBCL; 2L BTKi CDK4 activation drives BTKi resistance; CDK4/6i sensitizes MCL to ibrutinib (Chiron et al 2014). Positive clinical data in palbociclib/ibrutinib MCL study (Martin et al 2016). Melanoma BRAFm 1L MEKi + RAFi CDK4/6i enhances efficacy and extends time to resistance in preclinical models (Harris et al AACR 2017). MEKi + CDK4/6i are synergistic in BRAFm melanoma (Teh et al 2016). RASm basket CRC, pancreatic, cholangiocarcinoma MEKi CDK4/6 inhibitors enhance the efficacy of MEK inhibitors in KRASm tumors including CRC (Pek et al 2017, Ziemke et al 2015) and PDAC (Franco et al 2014, Franco et al 2016). GIST GIST; 3L after imatinib, sunitinib regorafenib GIST features CDKN2A loss/CCND1 amp (Yang et al 2008), which correlate with CDK4/6 inhibitor sensitivity. CDK4/6i is efficacious in imatinib resistant preclinical models (Eilers et al 2015).

Slide 34

G1T48 development program

Slide 35

G1T48: oral SERD, strong strategic fit Ibrance approved only in combination with an anti-estrogen first letrozole (aromatase inhibitor), then Faslodex (IM SERD) Multiple companies with oral SERDs in early development G1T48 provides a competitive advantage by controlling economics of a combination G1T38/48 regimen stand-alone opportunity in early stage disease Compelling preclinical data package (2017 AACR poster) more potent than Faslodex On track for IND filing in 4Q17

Slide 36

Key anticipated milestones through 2Q18 Trilaciclib (iv CDK4/6i) G1T38 (oral CDK4/6i) 1st line- SCLC Phase 2a 2nd/3rd-line SCLC Phase 2a metastatic TNBC Phase 2 1st line- SCLC, Ph2 (+ Tecentriq) EGFRm NSCLC Phase 1b/2 (+ Tagrisso) ER+, HER2- BC Phase 1/2a 3Q17 4Q17 1Q18 2Q18 G1T48 (oral SERD) Phase 1 initiated top-line randomized data Phase 1b initiated IND filed ER+, HER2- BC Ph1b/2a (+ Faslodex) Phase 1b enrollment completed; Phase 2a initiated enrollment completed IND filed Phase 1b preliminary data enrollment completed enrollment continuing (through 2018) enrollment completed (2Q17)

Slide 37


Slide 38

Extensive preclinical and Phase 1 MOA data Preclinical validation of trilaciclib demonstrating: transient and reversible G1 arrest of HSPCs protection of HSPCs from damage by chemo (myelopreservation) preservation of bone marrow and immune system function improved complete blood cell count recovery after chemo reduction of bone marrow exhaustion, superiority to GCSF prevention of myeloid skewing and consequent lymphopenia activation of effector T-cells in the tumor microenvironment enhancement of chemotherapy and checkpoint inhibitor anti-tumor efficacy Robust pharmacodynamic effect in 45 subject Phase 1a HNV trial transient G1 arrest of HSPCs trilaciclib well-tolerated, no DLTs or SAEs Recent presentations and publications meetings: AACR, ASCO, WCLC, EORTC/AACR/NCI Molecular Cancer Therapeutics (Bisi et al, 2016) Science Translational Medicine (He et al, 2017)

Slide 39

Advantages of trilaciclib vs. GCSF GCSF Trilaciclib Stimulates granulocyte-specific progenitors after damage by chemo Protects HSPCs from damage by chemotherapy Stimulates granulocyte production only Preserves all hematopoietic lineages Potential to reduce febrile neutropenia (if used prophylactically). No effect on other cytopenias Reduce all cytopenias and transfusions (platelets, RBCs), GCSF usage, febrile neutropenia, bleeding, hospitalizations No effect (other than on granulocyte production) Enhances immune system function (effector T-cells) during chemotherapy Exacerbates myeloid skewing Prevents myeloid skewing and consequent lymphopenia Accelerates bone marrow exhaustion Prevents bone marrow exhaustion Potential to increase secondary heme malignancies (MDS, AML) Potential to reduce secondary heme malignancies (MDS, AML) Injection-site irritation and bone pain Convenient IV administration before chemo, fits standard clinical practice Protein: high COGS Small molecule: low COGS

Slide 40

Short-acting pharmacology is key goal is to rapidly arrest HSPCs in G1, with HSPCs re-entering the cell cycle after chemotherapy T-cell stimulatory effect is seen with transient CDK4/6 inhibition prolonged CDK4/6 inhibition is detrimental: blocks T-cell proliferation and causes myelosuppression ideal PK profile: rapid Tmax, high Cmax, short t1/2 Timing of CDK4/6 inhibition and chemotherapy is critical trilaciclib’s IV dosing provides exquisite control and fits standard clinical practice for chemo/checkpoints trilaciclib Phase 1a bone marrow PD data demonstrate precise magnitude and duration of HSPC G1 arrest; IV PK/PD unknown for Ibrance Ibrance has highly variable PK compared to trilaciclib; if HSPCs are not fully arrested or re-enter the cell cycle too soon, can lead to serious myelosuppression (seen in Ibrance/Taxol combo clinical trial) Trilaciclib is a short-acting IV drug with reproducible and well-understood human PK/PD and clinical experience in over 130 patients with three different chemotherapy regimens Ibrance is a long-acting oral drug with CYP3A contraindications that accumulates with repeat dosing and has unknown human IV PK/PD Myelopreservation via CDK4/6 inhibition: advantages of trilaciclib vs. Ibrance

Slide 41

Drug IC50 (uM) CDK4 IC50 (uM) CDK6 IC50 (uM) CDK2-cyclin E IC50 (uM) CDK2-cyclin A CDK2-cyclinE/ CDK4 ratio CDK2-cyclin A/ CDK4 ratio trilaciclib 0.001 0.004 2.51 1.29 2510 1290 Ibrance 0.011 0.015 >10 >10 910 910 Trilaciclib has a very different human PK profile than Ibrance Drug Dose Tmax (h) Cmax (ng/ml) t1/2 (h)* trilaciclib IV 192mg/m2 0.47 1705 14.5 Ibrance PO 125mg 7 52 25.9 * Trilaciclib terminal elimination phase contributes very little to AUC, effective t1/2 ~ 8hrs. Ibrance accumulates with repeat dosing; trilaciclib does not accumulate. Trilaciclib data from He et al (Science Translational Medicine, 2017). Ibrance data from Flaherty et al (CCR, 2012). Trilaciclib is more potent than Ibrance Trilaciclib data from Bisi et al (MCT, 2016). Ibrance data from Fry et al (MCT, 2004).